Has William Santoro, MD received payments from drug or device companies?

Yes. Drug and device makers reported $92,596 in general payments to William Santoro, MD across 146 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Santoro, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Santoro, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Santoro, MD

Addiction Medicine · West Reading, PANPI 1326081241

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,152 of the $92,596 with a category attached, or 71.4%. 4 manufacturers reported payments, led by Indivior Inc. at 50.1% of the total. 2025 is the largest year on record at $33,355, 5.6 times the $5,980 reported in 2019. Among addiction medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$92,596in general payments, 2019–2025

Across 146 payments — averaging $634.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Indivior Inc.$46K
Braeburn Inc.$46K
Titan Pharmaceuticals, Inc.$250
Hikma Pharmaceuticals USA$22

What the payments were for

Consulting fees$9,74111%
Speaking & faculty fees$66,15271%
Travel & lodging$13,22014%
Food & beverage$3,4834%
Education$10%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Indivior Inc.	87	$46,361
Braeburn Inc.	57	$45,963
Titan Pharmaceuticals, Inc.	1	$250
Hikma Pharmaceuticals USA	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BRIXADI$45,280
SUBLOCADE$33,874
Probuphine$250

How this compares

$92,596 in reported general payments places this provider in the 95th percentile of 82 addiction medicine providers in Pennsylvania.

See all addiction medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$11,468

Medicare patients

Services billed

187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
SublocadeBuprenorphine	21	$43,010
VivitrolNaltrexone Microspheres	15	$23,102
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	120	$22,120
Buprenorphine	23	$10,005
Naltrexone Hcl	16	$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Indivior Inc.Sublocade	$46,361	$43,01021 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine	$22	$32,125143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 addiction medicine providers in Pennsylvania.